Abacavir, zidovudine, or stavudine as paediatric tablets for African HIV-infected children (CHAPAS-3): an open-label, parallel-group, randomised controlled trial.
about
The impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African childrenEffect of diurnal variation, CYP2B6 genotype and age on the pharmacokinetics of nevirapine in African children.Plasma Efavirenz Exposure, Sex, and Age Predict Virological Response in HIV-Infected African Children.Improved Adherence to Antiretroviral Therapy Observed Among HIV-Infected Children Whose Caregivers had Positive Beliefs in Medicine in Sub-Saharan AfricaSafety of zidovudine/lamivudine scored tablets in children with HIV infection in Europe and Thailand.Complications of Treatment in Youth with HIV.Should abacavir be a first-line alternative for adults with HIV in sub-Saharan Africa?Determinants of virological outcome and adverse events in African children treated with paediatric nevirapine fixed-dose-combination tablets.Survival of HIV-1 vertically infected children.Acute liver failure enhances oral plasma exposure of zidovudine in rats by downregulation of hepatic UGT2B7 and intestinal P-gp.Impact of Human Immunodeficiency Virus Drug Resistance on Treatment of Human Immunodeficiency Virus Infection in Children in Low- and Middle-Income Countries.Substituting Abacavir for Stavudine in Children Who Are Virally Suppressed Without Lipodystrophy: Randomized Clinical Trial in Johannesburg, South Africa.Optimizing Clinical Trial Design to Maximize Evidence Generation in Pediatric HIVLow prevalence of lipodystrophy in HIV-infected Senegalese children on long-term antiretroviral treatment: the ANRS 12279 MAGGSEN Pediatric Cohort Study
P2860
Q37030715-CAA36F14-2B22-4284-AABD-BEBA53D90AC9Q37509532-3095B7A6-7FF6-4C01-852C-4EF573C31C90Q37519804-E12E5048-C447-49DE-A4C8-1E5D42B97CB6Q37620109-564F7B53-7EAF-4862-B4A4-A008C6F5E63CQ37699739-7A41E639-0456-4846-87BD-498C459B84E0Q38846571-6318470F-F43D-4D70-BF8D-22EF4A2DB96CQ38849889-88449988-3941-43C2-9641-A7142F926551Q38851687-6E5F6922-CE4B-4DB9-82D9-7BC5C1791D44Q38975088-777B7E00-5902-4A6B-837B-B540EA0A41FEQ40108634-0439882C-B678-4610-B1F6-E92F97134C85Q45326130-B4BEAB78-5068-421C-85F1-3452DC368204Q47548671-25522599-A340-4619-B4E9-F2FAF00AE041Q56910418-325AC996-73AA-4563-A0BE-E863089E0011Q58798902-E519F0BF-8467-4605-BE1D-D50296711A75
P2860
Abacavir, zidovudine, or stavudine as paediatric tablets for African HIV-infected children (CHAPAS-3): an open-label, parallel-group, randomised controlled trial.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Abacavir, zidovudine, or stavu ...... , randomised controlled trial.
@ast
Abacavir, zidovudine, or stavu ...... , randomised controlled trial.
@en
type
label
Abacavir, zidovudine, or stavu ...... , randomised controlled trial.
@ast
Abacavir, zidovudine, or stavu ...... , randomised controlled trial.
@en
prefLabel
Abacavir, zidovudine, or stavu ...... , randomised controlled trial.
@ast
Abacavir, zidovudine, or stavu ...... , randomised controlled trial.
@en
P2093
P2860
P50
P1476
Abacavir, zidovudine, or stavu ...... , randomised controlled trial.
@en
P2093
A Sarah Walker
Adeodata Kekitiinwa
Adrian D Cook
Alice Asiimwe
CHAPAS-3 trial team
Chifumbe Chintu
Cissy Kityo
David Burger
Ellen Owen-Powell
George Abongomera
P2860
P304
P356
10.1016/S1473-3099(15)00319-9
P577
2015-10-05T00:00:00Z